India develops paper-based Covid-19 test for fast results
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 26, 2022
THURSDAY, MAY 26, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
India develops paper-based Covid-19 test for fast results

Coronavirus chronicle

UNB
05 October, 2020, 10:35 am
Last modified: 05 October, 2020, 01:30 pm

Related News

  • Bangladesh reports 28 new Covid cases in 24hrs
  • India's Kashmir sees upsurge in violence, tense after separatist convicted
  • 2 Indian satellites to be part Brics ‘virtual constellation’: Report
  • India exported wheat worth $473 million in April
  • Bangladesh logs 30 new Covid cases in 24hrs

India develops paper-based Covid-19 test for fast results

Feluda will be made by a leading Indian conglomerate, Tata, and could be the world's first paper-based Covid-19 test available in the market

UNB
05 October, 2020, 10:35 am
Last modified: 05 October, 2020, 01:30 pm
The new Feluda test uses a gene-editing technology to detect the virus. Photo: UNB
The new Feluda test uses a gene-editing technology to detect the virus. Photo: UNB

A team of scientists in India has developed an inexpensive paper-based test for coronavirus that could give fast results similar to a pregnancy test, reports BBC.

The test, named after a famous Indian fictional detective, is based on a gene-editing technology called Crispr.

Scientists estimate that the kit - called Feluda - would return results in under an hour and cost 500 rupees (about $6.75; £5.25).

Feluda will be made by a leading Indian conglomerate, Tata, and could be the world's first paper-based Covid-19 test available in the market.

"This is a simple, precise, reliable, scalable and frugal test," Professor K Vijay Raghavan, principal scientific adviser to the Indian government, told the BBC.

Researchers at the Delhi-based Institute of Genomics and Integrative Biology (IGIB), where Feluda was developed, as well as private labs, tried out the test on samples from about 2,000 patients, including ones who had already tested positive for the coronavirus.

They found that the new test had 96% sensitivity and 98% specificity. The accuracy of a test is based on these two proportions. A test that's highly sensitive will detect almost everyone who has the disease; and a test that's has high-specificity will correctly rule out almost everyone who doesn't have the disease.

The first ensures not too many false negative results; and the second not too many false positives.

India's drug regulator has cleared the test for commercial use.

The Institute of Genomics and Integrative Biology team behind the new test. Photo; UNB
The Institute of Genomics and Integrative Biology team behind the new test. Photo; UNB

With more than six million confirmed infections, India has the world's second-highest Covid-19 caseload. More than 100,000 people in the country have died of the disease so far.

After a slow start, India is now testing about 100,000 samples a day in more than 1,200 laboratories across the country. It is using two tests.

The first is the time-tested, gold standard polymerase chain reaction, or PCR swab tests, which uses chemicals to amplify the virus's genetic material in the laboratory.

The second is the speedy antigen test, which works by detecting virus fragments in a sample.

The Institute of Genomics and Integrative Biology team behind the new test

The PCR test is generally reliable and costs up to 2,400 rupees. It has low false positive and low false negative rates. The antigen tests are cheaper and use finger-prick blood samples to find signs of previous infection. They are more precise in detecting positive infections, but generate more false negatives than the PCR test.

Scaling up testing in India hasn't meant easy availability yet, according to Dr Anant Bhan, a researcher in global health and health policy.

"There are still long wait times and unavailability of kits. And we are doing a lot of rapid antigen testing which have problems with false negatives," Dr Bhan told the BBC.

He believes the Feluda test could potentially replace the antigen tests because it could be comparatively cheaper - and more accurate.

"The new test has the reliability of the PCR test, is quicker and can be done in smaller laboratories which don't have sophisticated machines," Dr Anurag Agarwal, director of IGIB, told the BBC.

Sample collection for the Feluda test will be similar to the PCR test - a nasal swab inserted a few inches into the nose to check for coronavirus in the back of the nasal passage. India still doesn't allow Covid-19 tests from saliva samples.

The new Feluda test uses Crispr - short form for Clustered Regularly Interspaced Short Palindromic Repeats - or a gene-editing technology to detect the virus.

According to researchers, gene-editing works in a way similar to word processing - it's like using the cursor to correct a typo by removing an incorrect letter and inserting the correct one. The technique is so precise it can remove and add a single genome letter. Gene-editing is mainly used to prevent infections and treating ailments like sickle cell disease.

When used as a diagnostic tool, like Feluda, the Crispr technology latches on to a set of letters of a gene carrying the signature of the novel coronavirus, highlights it, and gives a read-out on a piece of paper.

Two blue lines indicate a positive result, while a single blue line means the test has returned negative.

"Testing remains a limited resource and something that we need to do everything we can to improve its availability. So Feluda is an important step in that direction," said Dr Stephen Kissler, a research fellow at Harvard Medical School.

The Crispr-based tests are a part of a "third wave of tests" after the time consuming and labour intensive PCR and antigen tests, according to Dr Thomas Tsai of the Harvard Global Health Institute.

In the US and the UK, several companies and research labs are developing similar paper strip tests which can be cheap and mass produced. One of the most talked-about has been a paper-based strip developed by Sherlock Bioscience which has been cleared for emergency use by the US Food and Drug Administration (FDA). The test claims to detect the "unique genetic fingerprints of virtually any DNA or RNA sequence in any organism or pathogen". DNA and RNA are sister molecules responsible for the storage of all genetic information that underpins life.

"The ideal and ultimate test will be the one that is paper-based which you can do from home," said Dr Tsai. "But of course, there are some biological restrictions to the technology - we can't expect people to extract and amplify the RNA from home."

This is where the Feluda test might end up making a huge difference to the way we look at gene-editing based diagnostic tests.

Dr Debojyoti Chakraborty, a molecular scientist with IGBMR and a lead member of the team that developed Feluda, told the BBC that they were working on a prototype of a test where "you can extract and amplify the RNA using PCR at home".

"We are trying for a simple, affordable, and truly point-of-care test so widespread testing is not limited by machines and manpower," Dr Chakraborty said.

"India has the opportunity to show the value of this test, because it has such a big population and it's coming right at the time when it is needed," Dr Kissler said. "If their efficacy is demonstrated, it can have benefits that ripple around the world."

A vaccine will be vital for fully recovering from the pandemic, but according to Dr Kissler, reliable, accessible testing is also key to achieve "a sense of normalcy".

"In the ideal world I envision, taking a test will be as easy as brushing your teeth or making toast," he said.

Top News

India / paper / Covid -19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Tax amnesty, relaxed remittance rules to bring back laundered money: Kamal
    Tax amnesty, relaxed remittance rules to bring back laundered money: Kamal
  • Representational picture. Photo: Collected
    India likely to curb rice exports
  • Azam Nazeer Tarar presents the Election Amendment Bill in the National Assembly on Thursday. — Photo Courtesy National Assembly of Pakistan/Twitter
    Pakistan NA passes bill abolishing use of EVMs in election

MOST VIEWED

  • People in protective suits cross a street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    Shanghai heading out of lockdown but China still lost in economic gloom
  • A woman wearing a face mask crosses a road at the Central Business District (CBD), amid the coronavirus disease (Covid-19) outbreak in Beijing, China May 10, 2022. REUTERS/Carlos Garcia Rawlins
    Tightening Covid net, Beijing deals out punishments, stark warnings
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing ramps up Covid quarantine, Shanghai residents decry uneven rules
  • A vial labelled with the Pfizer-BioNTech coronavirus disease (Covid-19) vaccine is seen in this illustration picture taken March 19, 2021. Photo :Reuters
    Pfizer says 3 Covid shots protect children under 5
  • A medical worker takes a swab sample from a person for a nucleic acid test at a makeshift testing site, amid the coronavirus disease (Covid-19) outbreak, in Beijing, China May 23, 2022. REUTERS/Tingshu Wang
    Beijing urges millions to keep working from home amid Covid outbreak menace
  • Picture: PTI
    Saudi Arabia bans travel to India, 15 other countries over Covid outbreaks

Related News

  • Bangladesh reports 28 new Covid cases in 24hrs
  • India's Kashmir sees upsurge in violence, tense after separatist convicted
  • 2 Indian satellites to be part Brics ‘virtual constellation’: Report
  • India exported wheat worth $473 million in April
  • Bangladesh logs 30 new Covid cases in 24hrs

Features

Photo caption: Business models are already being hit by climate risk. It is the function of regulators to force banks to pay attention to the future risks to businesses. Photo: Bloomberg

HSBC and its discordant climate songbook

3h | Panorama
Illustration: TBS

Should Belayets be allowed to return to school at 55?

7h | Pursuit
Impact Hub Dhaka is designed to cater to connectivity, offering lots of communal areas where you can chat over coffee, watch a webinar as a group or even host events. Photo: Courtesy

Inside Impact Hub: The surprising benefits of working in a co-working space

8h | Pursuit
Pacific Jeans uses sustainable technology in washing and finishing, and now has the facility to wash with zero water. Photo: Courtesy

How big dreams and smart investment made Pacific Jeans a denim exporting giant 

9h | Panorama

More Videos from TBS

5 latest exciting movies

5 latest exciting movies

1h | Videos
Why is Thanda Garam's juice so popular?

Why is Thanda Garam's juice so popular?

7h | Videos
Tea tales at TSC

Tea tales at TSC

8h | Videos
What journalism students want to know

What journalism students want to know

9h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

3
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

4
Photo: Courtesy
Panorama

Misfit Technologies: A Singaporean startup rooted firmly in Bangladesh

5
Illustration: TBS
Banking

Let taka slide

6
Photo: Collected
Industry

Spanish recycled cotton producer opens new facility in Bangladesh

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab